Total costs were not reported.
For Crohn’s disease, the probability of response was 42.9% with adalimumab and 39.0% with infliximab. The probability of remission was 37.4% with adalimumab and 28.7% with infliximab. The cost per additional responding patient was $116,291 with adalimumab (40mg every other week) and $125,169 with infliximab (5mg/kg). When compared with each other, the incremental cost per responding patient with infliximab over adalimumab was $8,878. The incremental cost per remitting patient was $52,983.
For psoriasis, the rate of response was 68.5% with adalimumab, 51.1% with etanercept, 66.8% with ustekinumab (45mg), 72.0% with ustekinumab (90mg), and 79.0% with infliximab. The rate of remission were 39.6% with adalimumab, 22.3% with etanercept, 40.1% with ustekinumab (45mg), 44.3% with ustekinumab (90mg), and 51.7% with infliximab. The cost per additional responding patients was $9,756 with adalimumab, $21,770 with etanercept, $13,821 with ustekinumab (45mg), $25,327 with ustekinumab (90mg), and $12,828 with infliximab. The cost per additional remitting patient was $16,380 with adalimumab, $48,726 with etanercept, $22,322 with ustekinumab (45mg), $40,008 with ustekinumab (90mg), and $19,061 with infliximab.
For methotrexate-refractory rheumatoid arthritis, the rates of response and remission were highest with adalimumab and etanercept, and lowest with rituximab, infliximab, and abatacept. The lowest estimates of the cost per additional responding patients were $27,853 with adalimumab, $29,140 with etanercept, and $31,363 with tocilizumab. The lowest estimates of the cost per remitting patient were $47,533 with adalimumab and $48,320 with tocilizumab.
In the cross-indication analysis, the weighted average one-year cost per additional responding patient across the psoriasis and rheumatoid arthritis diseases was $56,219 for adalimumab $62,283 for etanercept and $82,683 for infliximab. Across all three diseases, adalimumab was associated with lower one-year costs per additional responding patient ($23,984) and remitting patient ($41,919) compared with infliximab.